|
|
http://www.dxy.cn/bbs/post/view?bid=116&id=9334084&sty=1&tpg=1&age=0<br/>??<br/>?关键词：肺癌疫苗 NEJM 文迪娅事件 股票<br/>??<br/>??GSK to launch five new drugs to tackle cancer <br/>??By Karen Attwood <br/>??Published: 19 June 2007 <br/>??GlaxoSmithKline, Europe's biggest drug-maker, is to launch five cancer drugs in the next three years as it increases its exposure to a lucrative £20bn market. <br/>??<br/>??The company, which has taken a hit in recent weeks after its diabetes drug Avandia was linked to an increased risk of heart attacks, has also unveiled plans to enrol the first patients in its lung-cancer vaccine trial, which will begin in September. Glaxo is competing with Germany's Merck to produce the first lung-cancer vaccine and will commence the largest late-stage study of a treatment for the disease, which kills around 1.3 million people worldwide each year.<br/>??<br/>??The five new oncology products set for launch by 2010 are the cervical cancer vaccine Cervarix; the renal cancer drug Pazopanib; Promacta, an oral compound to help cancer patients build up their platelet count and reduce bleeding; Rezonic, which helps to control symptoms associated with chemotherapy such as nausea; and Ofatumumab, an antibody to treat leukaemia which has blockbuster potential.<br/>??<br/>??Glaxo's head of research and development, Moncef Slaoui, called the target "an unprecedented objective for a pharmaceutical company". He said Glaxo was developing late-stage medicines in more than 12 types of cancer and had a significant number of compounds in early-stage discovery.<br/>??<br/>??Glaxo aims to establish itself as a major player in the oncology market, which is growing by 20 per cent annually.<br/>??<br/>??Recent developments at Glaxo have been overshadowed by the furore surrounding Avandia. Shares have lost 10 per cent of their value since a study in the New England Journal of Medicine in May linked the drug, the firm's second best seller, to an increased risk of heart attack. Although Glaxo disputes the findings, sales and prescriptions of the drug have been hit. Analysts have remained positive on the stock owing to the potential of the pipeline and said the share price fall due to the Avandia scare will prove to be excessive.<br/>??<br/>??Julien Dormois, health and life science analyst at Bryan Garnier, said Avandia remains a blockbuster and the impact of falling sales has already been priced in. He added: "It is becoming clearer and clearer that Glaxo may become the second major force for oncology worldwide behind Roche."<br/>??<br/>??For Glaxo's lung cancer trial, 2,200 patients diagnosed with non-small cell lung cancer, the most common form of the disease, will be treated with the vaccine. It is hoped the vaccine may prevent the cancer from returning following surgery and will enable patients to live longer by helping their immune systems to recognise and destroy cancer cells. Lung cancer has one of the lowest survival rates, with 85 per cent of patients dying within five years. <br/>??<br/>??<br/>??丁香园anmb1编译：<br/>??<br/>??<br/>??<br/>??GSK将5种治疗癌症新药投放市场<br/>??<br/>??<br/>??据英国《独立报》报道，欧洲最大的药品制造商——葛兰素史克公司，计划在未来三年内上市5种抗癌药物，以便在有利可图的200亿英镑的市场中扩大其份额。<br/>??<br/>??2010年之前计划投放市场的抗癌药物是：子宫颈癌疫苗Cervarix、肾癌药物Pazopanib、有助于癌症患者提高血小板数量和减少出血的口服药物Promacta、有助于控制化疗引起的恶心等症状的药物Rezonic以及可能成为重磅药物的治疗白血病抗体Ofatumumab。<br/>??<br/>??该公司研发部主管Moncef Slaoui声称，这一目标对于制药公司来说是史无前例的。他说，该公司针对超过12种类型癌症的治疗药物正处于后期开发阶段，还有大量的化合物处于早期研发阶段。葛兰素的目标是在年增长率为20%的肿瘤药物市场中扮演主要的角色。<br/>??<br/>??在最近几周因其治疗糖尿病药物文迪雅涉嫌增加心脏病发作风险而受重挫的该公司，最近也已向外界透露了九月份开始的最大规模的一项肺癌疫苗后期临床研究计划，2200名诊断为非小细胞肺癌这一最常见的肺癌的患者将纳入该疫苗临床试验，而首例病人即将入组。葛兰素与德国默克公司竞争开发首个肺癌疫苗，该疫苗有望预防肺癌术后复发，并将通过帮助免疫系统识别和摧毁癌症细胞来延长患者生命。肺癌是存活率最低的癌症之一，85%的患者在5年内将离开人世。即据估计，每年全世界范围内约130万人死于肺癌。<br/>??<br/>??葛兰素公司的近期发展因文迪雅事件而黯然失色。自5月份《新英格兰医学杂志》发表该药物（该公司第二大畅销药）与增加心脏病发作风险有关的文章以来，该公司股票已经下跌10%。尽管葛兰素对此提出抗议，但该药物销售量和处方量均受到打击。基于可能的渠道，分析家对其股票仍持正面评价，并称股票价值下跌原因是对文迪雅事件的过度恐惧。 Bryan Garnier投资公司健康和生命科学分析师Julien Dormois称，文迪雅仍然属于重磅炸弹级药物，销量下降的影响已被消化。他补充道，葛兰素继罗氏之后成为世界肿瘤药物市场第二大主力的迹象越来越明朗。<br/>??<br/>??<a href="http://blog.tianya.cn/blogger/post_show.asp?idWriter=0&Key=0&BlogID=1117859& ostID=10389853">http://blog.tianya.cn/blogger/post_show.asp?idWriter=0&Key=0&BlogID=1117859&ostID=10389853</a><br/> |
|
IP卡
狗仔卡
发表于 2007-7-22 11:21:04
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
抢沙发
千斤顶
显身卡